RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Peking University Third Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University Third Hospital北京大学第三医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07460362, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Diagnosis of MCL established by histologic assessment

    Inclusion criterion 4

  3. Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography [CT] scan)

    Inclusion criterion 9

    Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), (GTD)≥1.5 cm

    Inclusion criterion 12

  4. Combined with other malignant tumors within 3 years;

    Exclusion criterion 4

    Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07460362, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • • Signed Informed Consent Forms
  • Age: >= 18 to 80 years
  • Eastern Cooperative Oncology Group =< 2
  • Diagnosis of MCL established by histologic assessment
  • Previously treated with at least one prior line of systemic therapy for mantle cell lymphoma.
  • Prior therapy have included a BTK inhibitor, including ibrutinib, zanubrutinib, obrutinib, acalabrutinib and various BTKi in clinical trials. BTki exposure is required, which include BTKi failure or intolerance. BTKi failure is defined as progression of disease during BTKi therapy or patients have progressed or relapsed after completing BTK inhibitor therapy
  • At least one high risk features as classified:
  • Blastoid/pleomorphic variants ✔ Ki67 ≥50% ✔ TP53 mutation or deletion
  • Bulky disease (defined as any lesion ≥7.5 cm on the screening computed tomography [CT] scan)
  • Patients that did not achieve a CR with their first-line treatment
  • early disease progression (POD24) ✔ patients with relapse and refractory treatment above 3 lines
  • Measurable lesions on cross-sectional imaging documented by diagnostic imaging(MRI, CT or PET-CT), (GTD)≥1.5 cm
  • Adequate liver function : Total bilirubin =< 3 x upper limit of normal (ULN) (unless has Gilbert's disease), Aspartate aminotransferase (AST) =< 5.0 x ULN, Alanine aminotransferase (ALT) =< 5.0 x ULN

Exclusion Criteria:

  • • Already enrolled in other Ongoing interventional or non-interventional R/R MCL clinical trials;
  • Currently receiving immunosuppressive treatment for other diseases;
  • Previous treatment with lenalidomide;
  • Combined with other malignant tumors within 3 years;
  • The researcher determines that they are not suitable to participate in this study;
  • Serious mental or neurological disorders that affect informed consent and/or the expression or observation of adverse reactions;
  • Have a history of major or extensive cardiovascular disease, such as New York Heart Association class III or Grade IV heart disease or objective assessment, myocardial infarction, unstable arrhythmia or unstable angina within 6 months before the first cycle;
  • Recent major surgery (within 4 weeks before the start of the first cycle);
  • Active autoimmune diseases with poor treatment control;
  • Any active infection that may affect the safety of the participant, including bacterial, fungal and various viral infections, occurred within 7 days before the first day of cycle 1;
  • Positive SARS-CoV-2 PCR test within 7 days prior to enrollment
  • Positive test results for chronic hepatitis B infection (defined as positive hepatitis B surface antigen [HBsAg] serology) Participants with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if hepatitis B virus (HBV) DNA is undetectable at the time of screening. Such participants must be willing to undergo HBV DNA testing on Day 1 of every cycle and every 3 months for at least 12 months after the final cycle of study treatment and appropriate antiviral therapy as indicated.
  • Positive test results for hepatitis C (hepatitis C virus [HCV] antibody serology testing) Participants positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  • A history of severe deep vein thrombosis event or pulmonary embolism within 6 months
  • Patient follow-up was not possible.

Quoted from ClinicalTrials.gov, NCT07460362, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07460362, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07460362